AU2003217350A1 - Proliferated cell lines and uses thereof - Google Patents

Proliferated cell lines and uses thereof

Info

Publication number
AU2003217350A1
AU2003217350A1 AU2003217350A AU2003217350A AU2003217350A1 AU 2003217350 A1 AU2003217350 A1 AU 2003217350A1 AU 2003217350 A AU2003217350 A AU 2003217350A AU 2003217350 A AU2003217350 A AU 2003217350A AU 2003217350 A1 AU2003217350 A1 AU 2003217350A1
Authority
AU
Australia
Prior art keywords
cell lines
proliferated cell
proliferated
lines
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003217350A
Other versions
AU2003217350A8 (en
Inventor
Don F. Cameron
Pablo Caviedes
Raul Caviedes
Thomas B. Freeman
Paul R. Sanberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Chile
University of South Florida
Original Assignee
Universidad de Chile
University of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Chile, University of South Florida filed Critical Universidad de Chile
Publication of AU2003217350A1 publication Critical patent/AU2003217350A1/en
Publication of AU2003217350A8 publication Critical patent/AU2003217350A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/07—Coculture with; Conditioned medium produced by endocrine cells
    • C12N2502/078—Coculture with; Conditioned medium produced by endocrine cells thyroid, parathyroid cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
AU2003217350A 2002-02-08 2003-02-07 Proliferated cell lines and uses thereof Abandoned AU2003217350A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35515702P 2002-02-08 2002-02-08
US60/355,157 2002-02-08
PCT/US2003/003753 WO2003065999A2 (en) 2002-02-08 2003-02-07 Proliferated cell lines and uses thereof

Publications (2)

Publication Number Publication Date
AU2003217350A1 true AU2003217350A1 (en) 2003-09-02
AU2003217350A8 AU2003217350A8 (en) 2003-09-02

Family

ID=27734471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003217350A Abandoned AU2003217350A1 (en) 2002-02-08 2003-02-07 Proliferated cell lines and uses thereof

Country Status (6)

Country Link
US (3) US7416885B2 (en)
EP (1) EP1575524A4 (en)
JP (1) JP4741189B2 (en)
AU (1) AU2003217350A1 (en)
CA (1) CA2476214A1 (en)
WO (1) WO2003065999A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
EP1648380B1 (en) * 2003-07-03 2015-04-08 Sertoli Technologies, LLC Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
WO2007071068A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
WO2007094301A1 (en) * 2006-02-14 2007-08-23 Senju Pharmaceutical Co., Ltd. Vitreous cell line
US9102915B2 (en) * 2006-11-13 2015-08-11 DePuy Synthes Products, Inc. In vitro expansion of postpartum-derived cells using microcarriers
EP3078738B1 (en) 2007-08-31 2020-05-20 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2010008573A2 (en) * 2008-07-15 2010-01-21 Christopher Thanos Wound healing
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
SG174551A1 (en) 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
US9157907B2 (en) * 2010-04-30 2015-10-13 Universität Für Bodenkultur Wien Panels of immortalized mammalian cells and their use
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP2625577B1 (en) 2010-10-08 2019-06-26 Terumo BCT, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
CN102586171A (en) * 2011-01-07 2012-07-18 中国科学院上海生命科学研究院 Sheep induced pluripotent stem cell and preparation method thereof
JP5435116B2 (en) 2012-03-15 2014-03-05 株式会社リコー Powder container, powder replenishing device for replenishing developer from the powder container, and image forming apparatus on which it is mounted
WO2014130922A1 (en) * 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3068866B1 (en) 2013-11-16 2018-04-25 Terumo BCT, Inc. Expanding cells in a bioreactor
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
CN106715676A (en) 2014-09-26 2017-05-24 泰尔茂比司特公司 Scheduled feed
EP3277799B1 (en) 2015-04-03 2020-09-23 Propagenix Inc. Ex vivo proliferation of epithelial cells
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP6869231B2 (en) 2015-09-11 2021-05-12 プロパジェニクス インコーポレイテッド Proliferation of epithelial cells in ex vivo
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN109415696A (en) 2016-05-25 2019-03-01 泰尔茂比司特公司 Cell amplification
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN117247899A (en) 2017-03-31 2023-12-19 泰尔茂比司特公司 cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP6563145B2 (en) * 2017-08-09 2019-08-21 株式会社マンダム Immortalized sweat gland myoepithelial cells
JP2022517531A (en) * 2019-01-18 2022-03-09 アブラハム ジェイ アンド フィリス カッツ コード ブラッド ファウンデーション Double stem cell therapy for neurological disorders
KR102179902B1 (en) * 2019-08-08 2020-11-17 단국대학교 천안캠퍼스 산학협력단 Scaffolds for differentiation of odontoblast and method for differentiation of odontoblast using the same
CN113632765B (en) * 2021-03-31 2023-01-03 中山大学中山眼科中心 Retina neovascular disease animal model, construction method and application thereof

Also Published As

Publication number Publication date
US20080175828A1 (en) 2008-07-24
CA2476214A1 (en) 2003-08-14
US8137662B2 (en) 2012-03-20
JP2005524633A (en) 2005-08-18
EP1575524A4 (en) 2008-11-05
US8337829B2 (en) 2012-12-25
JP4741189B2 (en) 2011-08-03
AU2003217350A8 (en) 2003-09-02
US20030232752A1 (en) 2003-12-18
WO2003065999A2 (en) 2003-08-14
EP1575524A2 (en) 2005-09-21
US7416885B2 (en) 2008-08-26
WO2003065999A3 (en) 2006-08-10
US20120148540A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
AU2003217350A1 (en) Proliferated cell lines and uses thereof
AU2003299778A1 (en) Antibodies against gpr64 and uses thereof
AU2003272187A1 (en) Novel nanoparticles and use thereof
AU2003282478A1 (en) Discount-instrument methods and systems
AU2003270341A1 (en) Modified asialo-interferons and uses thereof
AU2003243531A1 (en) Fermentation methods and compositions
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
EP1539941A4 (en) Adzymes and uses thereof
AU2003221173A1 (en) Placenta-origin mesenchymal cells and medicinal use thereof
AU2003293644A1 (en) Moldings and preparation and uses thereof
AU2003278770A1 (en) Electrochemical cells and systems
AU2003271183A1 (en) Block copolymer and application thereof
AU2003296369A1 (en) Imminoamines and preparation thereof
AU2003266282A1 (en) Compositions comprising muscle progenitor cells and uses thereof
AU2003232075A1 (en) Modified t lymphocytes and uses therefor
AU2003231827A1 (en) Pseudo-tissues and uses thereof
EP1496122A4 (en) Novel meloidogyne-resistance gene and utilization thereof
AU2003228355A1 (en) Adipocytes and uses thereof
AUPS198302A0 (en) Improvements in bowsprits
AU2003262744A1 (en) Alpha-AMYLASE ASSAY AND USES THEREOF
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003220265A1 (en) Tamperproof and counterfeit-resistant structure
AU2003252514A1 (en) Sub-sequentia module and call
AU2003216442A1 (en) Enkurin and uses thereof
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase